aTyr Pharma (LIFE) Reports Q3 Loss of $0.24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update
November 13, 2018 4:05 PM EST- Initiation of Proof-of-Concept Study in Patients with Pulmonary Sarcoidosis Planned for Fourth Quarter of 2018 - Â Â Â Â Â Â Â Â Â Â Â Â - Conference Call Today at 5:00 p.m. ET / 2:00 p.m. PT
SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results for the third quarter ended September 30, 2018.
We continue to advance the development of our lead product candidate, ATYR1923, and have selected pulmonary sarcoidosis as the indication... More
